1. ""We continue to make excellent progress advancing CDX-1127..."
There are 2 arms to the 1127 trial: solid and hematologic cancers. 1127 has completed dose escalation in solid tumors and is currently in expansion phase in metastatic melanoma and renal cell carcinoma. The hematologic arm is enrolling in the dose escalation phase and will move into expansion by YE. Based on the "excellent progress" remark, my interpretation is that both arms of the trial are going well, with no safety issues and perhaps preliminary signals of efficacy based on the expansion into specific indications in the solid cancers arm of the trial.
2, "...which we believe is resulting in rapid translation of exciting immunostimulatory antibodies into the clinic...." As above, "rapid" and "exciting" imply positive preliminary results being observed.
3. Timing of PR: I don't know if it's just coincidence or astute management of news flow, but today's NEJM has 2 landmark studies on immunodulators in melanoma (nivolumab+ipilimumab, and lambrolizumab, respectively). The published trial results are remarkable, revolutionary even, and will attract a lot of attention to the field of immunomodulatory therapy. Relevant to CLDX, ipilimumab was developed through PII at Medarex by the same clinical team that is developing CDX-1127 at CLDX.
Today was a significant step in the evolution of immunomodulatory cancer therapies, and although there is a lot of work to be done on the development of CDX-1127, it looks like CLDX is in the thick of things in a very exciting cancer treatment field.
I tried posting the links but Yahoo won't allow it. Try googling "nejm", and the articles in question will be on the left hand side in the "original articles" column. Should be able to access the abstracts, full lengths articles need subscription or pay-to-read.
Thank you for your perspective on the announcement. It sure seems that management used the PR timing to point out that CLDX is right in the middle of the latest and hottest technologies in defeating cancers of all types. Your contributions to this message board are highly appreciated!